In a study employing B16-OVA melanoma, Panc-OVA pancreatic, and TRAMP-C1 prostate cancer mouse tumor models, the simultaneous administration of an ISCOMATRIX vaccine with poly(I:C) and a TLR9 agonist resulted in a significant reduction in tumor growth across all models [16]. The gene discussed is TLR9; the disease is neoplasm.